The Maraviroc Switch (MARCH) study week 48 data demonstrated that maraviroc, a chemokine receptor-5 (CCR5) inhibitor, was a safe and effective switch for the ritonavir-boosted protease inhibitor (PI/r) component of a two nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] plus PI/rbased antiretroviral regimen in patients with R5-tropic virus. Here we report the durability of this finding.
Introduction
The main aims of recently completed and ongoing treatment switch studies in HIV infection have been to explore the safety and efficacy of new treatment paradigms using either new formulations of existing drugs or novel partnering of licensed antiretroviral/antiviral agents. The rationale for this approach is as follows: first, to reduce longer term side effects and comorbidities, for example cardiovascular disease and bone disease, to which some current antiretroviral regimens may contribute; secondly, to reduce the lower grade but persistent side effects, such as diarrhoea, that may negatively impact quality of life, and subsequently affect treatment adherence [1] [2] [3] .
We have previously reported the week 48 findings from the MARCH study [4] . In summary, these data demonstrated that maraviroc (MVC) as a switch for a ritonavirboosted protease inhibitor (PI/r) with retention of the dual nucleoside/nucleotide reverse transcriptase inhibitor [2N(t) RTI] backbone was safe and effective. In contrast, the N(t) RTI-sparing switch arm, consisting of PI/r with MVC, was significantly inferior with regard to virological control compared with the control, PI/r + 2N(t)RTI arm (which we will refer to henceforth as the PI/r arm) over 48 weeks of follow-up. As a consequence, at the completion of week 48, the MVC + PI/r arm was discontinued, participants were informed of the results and site clinicians were advised to switch these participants away from this N(t)RTI-sparing combination. The other two arms of the study continued as planned. Here we report the 96-week data for the control (PI/r) and MVC + 2N(t)RTI (MVC) arms.
Methods
Study design, study population and assessments were as described for the published 48-week data [4] . The protocol and patient information statement and consent form were approved by the Ethics Committee/Institutional Review Board at all participating sites. Written informed consent was obtained from all participants (ClinicalTrials.gov number: NCT01384682). Assessments in year 2 of the study consisted of face-to-face visits at weeks 60, 72, 84 and 96 at which an assessment of vital signs, a targeted physical examination, a review of antiretroviral therapy and concomitant medications, an adverse event assessment, routine measurements including measurements of plasma HIV-1 RNA [plasma viral load (pVL)] and T-cell subsets, and safety laboratory tests were performed. Additional annual assessments (weeks 48 and 96) included assessments of fasted (≥ 8 h) lipid and glycaemic parameters, anthropometric measurements, bone mineral density (BMD) and dual-energy X-ray absorptiometry (DXA) measurements, and a quality-of-life (QoL) assessment using the twelve-item short form survey (SF-12) patient-completed questionnaire. The 7-day recall adherence tool was repeated at week 96. Stored samples were collected at all visits, with additional samples collected at the time of confirmed virological failure using the algorithm previously described [4] . MVC was dosed twice daily (bid), at a standard dose of 300 mg bid [5] .
Endpoints
The MARCH study had a number of other predefined secondary endpoints, including virological, immunological, metabolic/body composition, safety, adherence and QoL.
Statistical analysis
The first participant was randomized on 19 January 2012 and the last participant was randomized on 12 February 2014. The last randomized participant completed 96 weeks of follow-up or had permanently withdrawn from follow-up by the end of January 2016. As previously described, the switch arm was defined as noninferior if the lower limit of the 95% confidence interval (CI) for the difference was < À12% in the intention-to-treat (ITT) population. Safety endpoints (the difference in the mean change from baseline or a comparison of proportions) were analysed according to randomization arm. All statistical tests were two-sided and considered significant at a < 0.05. Statistical analyses were performed in SAS 9.4 (SAS Institute, Cary, NC) and STATA 13 (StataCorp LLC4905 Lakeway DriveCollege Station, Texas).
Results
The last randomized participant completed 96 weeks of follow-up (or had permanently withdrawn) by the end of January 2016. Data for this analysis were extracted on 27 February 2016.
Participant disposition
The ITT population for this 96-week analysis comprised 238 participants (82 PI/r and 156 MVC participants), who commenced randomized therapy, attended the baseline visit and had at least one study visit. Seventy-one (87%) PI/r and 130 (83%) MVC participants were in follow-up and on therapy at week 96.
Baseline characteristics
Baseline characteristics have been previously described in the week 48 published data [4] and were well balanced across the two arms. As noted previously, abacavir/lamivudine was used in 22% of those in the PI/r arm vs. 12% of those in the MVC arm; the most common PI/r was ritonavir-boosted atazanavir followed by ritonavirboosted lopinavir; the latter was used in 35% and 21% of those in the PI/r and MVC arms, respectively.
Outcomes at week 96
Virological outcomes As shown in Table 1 , in the ITT analysis, 89.0% and 92.7% of the PI/r arm and 90.4% and 91.7% of the MVC arm had virological suppression to thresholds of < 50 and < 200 copies/mL, respectively, at week 96.
Both results were within the 95% CI bounds defined in the protocol, demonstrating that the MVC switch arm was virologically noninferior to the PI/r arm. In the 'per protocol' analysis (Table 1) , the MVC arm was noninferior to the PI/r arm, with pVL < 50 and < 200 copies/mL in 96.9% and 98.5% of participants vs. 94.4% and 98.6% in the PI/r arm at week 96, respectively.
Change to randomized therapy, reasons for stopping randomized therapy and self-reported adherence The hazard ratio for changes to randomized therapy over 96 weeks was 1.31 (95% CI 0.67, 2.56) for the MVC arm vs. the PI/r arm (Fig. 1) . Similar proportions, i.e. 13% and 17%, of participants in the PI/r and MVC arms, respectively, stopped randomized therapy. There were nine different reasons given for stopping randomized therapy; the commonest reasons given were participant decision [27% (n = 7) vs. 9% (n = 1) in the MVC arm vs. the PI/r arm, respectively), adverse event [23% (n = 6) vs. 9% (n = 1), respectively], 'high' HIV RNA [19% (n = 5) vs. 9% (n = 1), respectively] and physician decision [15% (n = 4) vs. 18% (n = 2), respectively].
Adherence
At week 4, all participants in whom the 7-day recall data had been captured as per protocol (96%) reported taking all or most of their pills in the 7 days prior to the week 4 visit; no participants reported taking none of their pills. At week 96, data were available for 95% of participants (n=227), of whom 73 (91%), six and one and 137 (93%), nine and one of those in the PI/r and MVC arms, respectively, reported taking all, most or none of their pills in the 7 days prior to the week 96 visit. Over 96 weeks, the MVC arm had a mean decrease in total cholesterol (À0.46 mmol/L), triglyerides (À0.41 mmol/L) and low-density lipoprotein (LDL) cholesterol (À0.22 mmol/L); these declines were significant for both total cholesterol (P = 0.0229) and triglycerides (P < 0.001), with a trend towards significance for the changes in LDL cholesterol (P = 0.0916) compared with the PI/r arm. Over 96 weeks, there were no significant percentage changes in physical or mental QoL domains on the SF-12 for the PI/r vs. MVC switch arms.
Safety findings over 96 weeks
Seventy-nine per cent of the PI/r arm and 87% of the MVC arm (P = 0.146) reported at least one adverse event during the study; of these, none were grade 4. Of the 863 events reported, the majority were either grade 1 (total 542 adverse events; 204 in the PI/r arm and 338 in the MVC arm) or grade 2 (total 304; 85 in the PI/r arm and 219 in the MVC arm). Very few events were considered definitely or probably related to the study drugs with only three events investigator-determined as definitely related (all in the PI/r arm); 16 adverse events in the MVC arm and 13 in the PI/r arm were considered probably related. Ninety-two per cent and 89% of adverse events were considered not related or probably not related to the study drug in the MVC and PI/r arms, respectively. Adverse events leading to a change in study medication occurred in none of the PI/r participants and three of the MVC group (P = 0.553). Overall, there were 28 (12%) serious adverse events reported, 10 (12%) in the PI/r arm and 18 (11.5%) in the MVC arm, respectively; none was considered related to the study drug.
Resistance
In the week 96 analysis, five individuals (two PI/r and three MVC participants) met the criteria for virological failure; the viral load at confirmed failure was low, i.e. between 282 and 2006 copies/mL. The reasons for the virological failure in the MVC arm were probably related to nonadherence in one participant (no genotypic resistance detected and R5-tropic virus detected on repeat tropism testing), and to emergent X4 virus in one participant with a minor PI mutation (L33I) and the M184V mutation (tropism testing was not possible because the sample failed to amplify). In the two PI/r virological failures, tropism testing was not possible because of failure to amplify the sample in both cases; in one participant 
Discussion
MARCH is the largest randomized study using genotypic assessment of viral tropism to determine the likelihood of MVC activity in a switch setting. Suppression of plasma viraemia to below the level of quantification, i.e. < 50 copies/mL, the current threshold for most guidelines in high-income settings (1), was similar between the arms, demonstrating the durability of the virological response to MVC over 96 weeks. Importantly, switching to MVC was associated with significant lipid benefits that might be important in the long term in reducing cardiovascular risk. Both PI/r and MVC were safe and well tolerated. While there has been a drive for oncedaily dosing for antiretroviral therapy (1, 2) , the twicedaily dosing of MVC did not appear to be associated with an adherence cost as captured in the 7-day recall.
There was a slightly increased risk of switching away from randomized therapy in the MVC arm compared with the PI/r arm, but to what extent this might have been driven by twice-daily dosing is unclear. Lastly, in the very few patients with confirmed virological failure, the emergent resistance mutations, in those for whom there was successful amplification enabling a genotype and/or tropism assay to be performed, were only associated with the loss of future use of MVC, not other classes of antiretrovirals. In summary, this large international randomized study demonstrates that MVC with a 2 N(t)RTI backbone, in those with R5-tropic virus measured using pro-viral DNA, is a switch/simplification option for a ritonavir-boosted protease inhibitor plus 2 N(t)RTI regimen, showing durable virological suppression, favourable metabolic changes and good tolerability over 96 weeks.
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